1. In Vivo
  2. >>Global Vision

Hologic Grabs Gen-Probe

Women’s health-focused Hologic is buying molecular diagnostics provider Gen-Probe for $3.7 billion in cash. Adding Gen-Probe’s automated instrument platforms gives Hologic critical mass in the molecular diagnostics market while allowing it to maintain its core focus on women’s health. Hologic’s international direct sales force and dealer network can further drive adoption of US-oriented Gen-Probe’s tests in both developed and emerging markets. It also gives Gen-Probe a much greater capability for selling to physicians as well as labs, filling a second significant gap in Gen-Probe’s marketing.

A year ago, Novartis AG, Thermo Fisher Scientific Inc., Danaher Corp., and Life Technologies Corp. were rumored suitors for molecular diagnostics provider Gen-Probe Inc. Gen-Probe is indeed turning itself over, but to women’s health-focused Hologic Inc., a supplier of diagnostics, imaging and surgical products. Hologic, roughly half the size of any of those others and barely larger than Gen-Probe itself, appears to be a good fit.

Adding Gen-Probe’s automated instrument platforms gives Hologic critical mass in the molecular diagnostics market while allowing it to maintain its core focus on women’s health. Hologic’s international direct sales force...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

 
• By Brian Yang

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

More from In Vivo

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By Ashley Yeo

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

Podcast: “Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

 
• By Anabel Costa-Ferreira

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

 
• By David Wild

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.